eSOL and Kalray Extend Their Cooperation to Address Demanding Needs of Automotive, Industrial and Medical Applications
Kalray (Euronext Growth Paris: ALKAL), a pioneer in processors for new intelligent systems, and eSOL (Tokyo Stock Exchange Mothers: 4420), a leading developer of real-time embedded software solutions, announce today the availability of eSOL’s eMCOS POSIX1 Real Time Operating System (RTOS) on Kalray’s MPPA® intelligent processor to address growing and demanding needs for performance, safety and security of Automotive, Industrial and Medical Markets. This support extends the already existing eMCOS Core profile that has been available for several years on the MPPA architecture.
eSOL is recognized as a key actor of embedded markets such as automotive, especially thanks to its contribution to AUTOSAR (“AUTomotive Open System Architecture”), the worldwide development partnership of automotive interested parties. Such a partnership enables the usage of a wide range of applications on Kalray MPPA® processor including advanced control frameworks like Robot Operating System for robot control, Autoware for autonomous driving, and other embedded software frameworks. Furthermore, eSOL has a strong presence and experience on medical and industrial markets.
“Massive system consolidation especially on the automotive domain, are now becoming realistic architecture option with the impressive amount of power available on the current and next-generation of Kalray’s intelligent processor” said Masaki Gondo, eSOL CTO. “eSOL and Kalray will continue this fruitful cooperation to provide relevant optimized and integrated solutions to satisfy our joint customers’ ever-growing needs for performance, safety and security.”
"Disruptive technology such as Kalray’s MPPA needs development environment such as eSOL’s eMCOS to enable smooth adoption at customers for a wide and growing range of applications. eMCOS POSIX provides a full-featured RTOS ensuring POSIX compatibility to OEMs, with the capability to execute multiple applications in parallel” said Stéphane Cordova, Vice-President of Embedded Business Unit at Kalray, “Combining eMCOS with the high performance of MPPA® processors gives customers a unique solution for a fast ramp up."
The usage of MPPA® in industries like automotive is facilitated using development environments that ease the adoption by customers, both OEMs and Tier-1s. This is the case for eSOL POSIX multi-process RTOS that offers the capability to define complex systems such as autonomous vehicles.
Such rich OS and middleware takes advantage of all the benefits of Kalray’s MPPA architecture and provides a consistent environment for customers to transition from MPPA® 2nd generation Bostan to 3rd generation Coolidge, reusing similar tools to develop applications.
eSOL’s unique distributed microkernel architecture enables optimal use of manycore processors such as Kalray’s MPPA®. While eMCOS Core provides a PSE51 single-context POSIX API for high-performance parallel computing, eMCOS POSIX adds PSE53 multi-process POSIX support for advanced software integration where more memory is available.
eSOL and Kalray are also cooperating to provide AUTOSAR-compliant software platforms, including both AUTOSAR Classic Platform and Adaptive Platform, to conform to modern automotive standards. This integration will help customers aggregate more functions on MPPA®-based systems, while still meeting the isolation and safety level requirements.
ABOUT ESOL CO., LTD.
eSOL is a leading embedded software developer that enables customers to accelerate the development of applications based on high-end embedded processors, including multi-core. eSOL’s advanced, scalable, and multi-profiled real-time operating systems are tightly integrated with development tools and middleware components to create flexible development platforms used by OEMs and ODMs worldwide in competitive vertical markets such as automotive, consumer electronics, industrial and medical equipment, and aerospace. Founded in 1975, eSOL is based in Tokyo, Japan. For more information, please visit www.esol.com
Trademark Notices: eSOL, eSOL Co.,Ltd and eMCOS are registered trademarks or trademarks of eSOL Co., Ltd in Japan and other countries.
Kalray (Euronext Growth Paris — FR0010722819 — ALKAL) is the pioneer in processors for new intelligent systems. As a real technological breakthrough, “intelligent” processors have the capability to analyze on the fly, and in an intelligent manner, a very large amount of information, and to make decisions and interact in real time with the outside world. These intelligent processors will be deployed extensively in fast-growing sectors, such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as healthcare equipment, drones, and robots. Kalray’s offering encompasses both processors and complete solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l'énergie atomique et aux énergies alternatives”, the French Alternative Energies and Atomic Energy Commission), Kalray serves customers such as server manufacturers, intelligent system integrators, and consumer product manufacturers, including car makers. For more information, visit www.kalrayinc.com.
1SIX: The Portable Operating System Interface is a family of standards specified by the IEEE Computer Society for maintaining compatibility between operating systems.
Tel. 04 76 18 90 71
ACTUS finance & communication
Tel. 01 53 67 36 79
Tel. 04 76 18 90 71
ACTUS finance & communication
Tel. 04 72 18 04 92
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu